title: Chimeric antigen receptor therapy for chronic lymphocytic leukemia: what are the challenges?
abstract: Chimeric antigen receptor (CAR)-modified T cells targeting CD19 expressed by normal and malignant B cells is a unique therapy for patients with chronic lymphocytic leukemia (CLL); recent results highlight the potential of this therapy for patients with relapsed CLL. Because adoptive transfer of CAR-modified T cells is a novel approach, there are issues for the medical oncologist to consider when evaluating current and future clinical trials for CLL patients. This article reviews the impact of CAR design, T-cell production, T-cell dose, conditioning regimens, and tumor burden at the time of CAR-modified T-cell infusion on the efficacy of this therapy.
authors.affiliation: Leukemia Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
authors.forename: Marco L
authors.initials: ML
authors.lastname: Davila
authors.forename: Renier
authors.initials: R
authors.lastname: Brentjens
mesh_terms: D000818:Animals; D018941:Antigens, CD19 / Q000276:immunology / Q000378:metabolism; D002986:Clinical Trials as Topic; D006801:Humans; D016219:Immunotherapy, Adoptive; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000235:genetics* / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D011946:Receptors, Antigen / Q000037:antagonists & inhibitors* / Q000235:genetics* / Q000276:immunology; D011994:Recombinant Proteins; D013601:T-Lymphocytes / Q000276:immunology / Q000378:metabolism; D047368:Tumor Burden
chemical_list: D018941:Antigens, CD19; D011946:Receptors, Antigen; D011994:Recombinant Proteins
references.citation: N Engl J Med. 2011 Aug 25;365(8):725-33
references.pmid: 21830940
references.citation: Blood. 2011 Nov 3;118(18):4817-28
references.pmid: 21849486
references.citation: Blood. 2012 Jan 19;119(3):696-706
references.pmid: 22117050
references.citation: J Exp Med. 1995 May 1;181(5):1653-9
references.pmid: 7722445
references.citation: Proc Natl Acad Sci U S A. 2009 Mar 3;106(9):3360-5
references.pmid: 19211796
references.citation: Blood. 2012 Apr 26;119(17):3940-50
references.pmid: 22308288
references.citation: Blood. 2012 May 3;119(18):4133-41
references.pmid: 22354001
references.citation: Blood. 2009 Dec 24;114(27):5454-63
references.pmid: 19880489
references.citation: J Clin Invest. 2011 May;121(5):1822-6
references.pmid: 21540550
references.citation: Science. 2003 Oct 17;302(5644):415-9
references.pmid: 14564000
references.citation: J Immunol. 2010 Feb 15;184(4):1885-96
references.pmid: 20089697
references.citation: Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5426-35
references.pmid: 17855649
references.citation: Cancer Res. 2006 Nov 15;66(22):10995-1004
references.pmid: 17108138
references.citation: Sci Transl Med. 2012 May 2;4(132):132ra53
references.pmid: 22553251
references.citation: Blood. 2010 Nov 11;116(19):3875-86
references.pmid: 20631379
references.citation: Mol Ther. 2009 Aug;17(8):1453-64
references.pmid: 19384291
references.citation: Mol Ther. 2010 Feb;18(2):413-20
references.pmid: 19773745
references.citation: Sci Transl Med. 2011 Aug 10;3(95):95ra73
references.pmid: 21832238
references.citation: Nat Med. 2003 Mar;9(3):279-86
references.pmid: 12579196
references.citation: Nat Rev Immunol. 2012 Mar 22;12(4):269-81
references.pmid: 22437939
references.citation: Biol Blood Marrow Transplant. 2010 Sep;16(9):1245-56
references.pmid: 20304086
references.citation: Nat Biotechnol. 2002 Jan;20(1):70-5
references.pmid: 11753365
references.citation: Blood. 2012 Mar 22;119(12):2709-20
references.pmid: 22160384
references.citation: N Engl J Med. 2004 Jun 10;350(24):2526-7; author reply 2526-7
references.pmid: 15190153
references.citation: Blood. 2003 Feb 15;101(4):1637-44
references.pmid: 12393484
references.citation: Cancer Cell. 2003 May;3(5):431-7
references.pmid: 12781360
references.citation: Blood. 2010 Nov 18;116(20):4099-102
references.pmid: 20668228
references.citation: J Clin Oncol. 2008 Nov 10;26(32):5233-9
references.pmid: 18809613